X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Lead Product(s): saRNA-based Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: University Medical Center Utrecht
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 29, 2024
Details:
RAG-01 stands as a pioneering saRNA candidate from Ractigen Therapeutics, engineered to target and activate the tumor suppressor gene p21, intended for non-muscle-invasive bladder cancer.
Lead Product(s): RAG-01
Therapeutic Area: Oncology Product Name: RAG-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
RAG-17 is a siRNA drug designed to provide potent and durable knockdown of SOD1 protein in the central nervous system (CNS) of ALS patients to prevent motor neuron degradation and delay disease progression.
Lead Product(s): RAG-17
Therapeutic Area: Neurology Product Name: RAG-17
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
RAG-17 is a therapeutic siRNA designed to target and knockdown the expression of SOD1 gene in patients with pathogenic mutations known to cause amyotrophic lateral sclerosi.
Lead Product(s): RAG-17
Therapeutic Area: Neurology Product Name: RAG-17
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
Ractigen will use this capital to advance several programs from preclinical to clinical phase, as well as scale-up its oligonucleotide manufacturing capabilities including its lead product RAG-06.
Lead Product(s): RAG-06
Therapeutic Area: Genetic Disease Product Name: RAG-06
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: SDIC Venture Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
